Israel Figas guide to U.S. market entry for pharma and medical device distributi

[RobertMiller]

A Practical Checklist for Choosing a U.S. Distributor for Pharma and Medical Products

Entering the U.S. market with a pharmaceutical product or medical device requires more than finding a company willing to distribute it. A suitable partner must fit the product's regulatory status, customer base, handling needs, and commercial goals. The choice can affect launch timing, access to healthcare buyers, inventory management, and the quality of market feedback. For companies assessing options, a structured review is more reliable than choosing on reach or price alone. This guide sets out a practical checklist for comparing distributors, testing their capabilities, and defining a working relationship. It also places the subject in the context of Israel Figa's work with pharmaceutical companies and business development, as described on the page. The aim is to support informed evaluation, not to imply that one distribution model suits every product or company.

Define the U.S. Market Requirements Before Contacting Distributors

Before contacting U.S. distributors, define the product's target customer and the purchasing pathway. A prescription medicine may be sold through wholesalers to pharmacies or health systems, while a medical device may require access to hospitals, clinics, laboratories, or specialized suppliers; the intended channel affects account priorities and logistics. Set measurable launch objectives, including geography, timing, first-year volume, and the evidence that would indicate progress. These assumptions establish the scope of US market entry and prevent discussions from substituting a distributor's general capabilities for a product-specific plan.

Confirm applicable U.S. regulatory status, product classification, labeling, and any required registrations or authorizations with qualified regulatory professionals before seeking offers. Requirements vary by product and intended use, and neither a distributor's interest nor its routine handling of products establishes that a product is ready for sale.
Assign responsibility separately for regulatory representation, promotion, order fulfillment, and customer service, since distribution alone does not necessarily include these functions. Prepare a checklist with the product dossier, labeling, evidence, and regulatory-status summary; target accounts, channels, launch geography, and volume forecast; and questions about ownership of promotion, compliance coordination, fulfillment, customer service, and reporting. The page's description of pharma and business-development work by Israel Figa provides relevant context for treating commercial planning as distinct from regulatory advice.

Verify Distribution Operations, Coverage, and Customer Access

Operational due diligence should confirm experience with products of comparable regulatory status, storage needs, clinical use, and customer workflows. Request anonymized case examples showing the candidate's role, territories, launch dates, and service scope, then verify claims through references. Map state and customer-segment coverage, separating direct staff from representatives, brokers, and subdistributors. Ask for channel diagrams, account types, call-frequency data, and evidence of access to relevant hospitals, clinics, pharmacies, or other buyers.

Assess fulfillment through a walkthrough of each facility that may store or ship the product. Examine receiving, lot and serial-number capture, expiry monitoring, quarantine, access controls, inventory counts, and recall procedures. For controlled or temperature-sensitive goods, request monitoring records, excursion reports, shipping qualification evidence, packaging specifications, and contingency plans. Written service descriptions should define order cutoffs, dispatch times, delivery confirmation, inventory visibility, and responsibility for loss or delay; request sample records rather than relying on assurances.

For medical device distribution, confirm that staff training matches intended use and that technical support covers installation, troubleshooting, and maintenance where applicable. Review training logs, service hours, escalation paths, return procedures, and complaint-routing processes, including prompt transfer of adverse-event information to the manufacturer. Requirements vary with product classification, claims, storage conditions, and each party's role, so qualified regulatory and legal advisers should verify applicable obligations. During distribution partner selection, references and written procedures can verify promised reach and expose operational gaps before launch.

Assess Commercial Fit, Incentives, and Launch Support

Assess commercial fit by comparing the distributor's proposed route to market with the product's target customers, positioning, and company objectives. The plan should identify priority segments, such as hospitals, specialty clinics, pharmacies, or health systems, and explain how each will be reached. Evaluate whether the sales team has relevant account relationships, sufficient capacity, and clear responsibilities for territory coverage, training, and follow-up. A launch timeline should specify sequencing, dependencies, expected decision points, and the resources needed to meet realistic adoption goals.

Marketing support should be defined in practical terms, including approved materials, educational activities, channel coordination, and who pays promotional expenses. Ask how market feedback will be collected, validated, and shared, including customer objections, pricing responses, competitor activity, and product access barriers. Commercial terms deserve scrutiny alongside the plan: compare pricing assumptions with net revenue expectations, clarify distributor margins and deductions, and test minimum purchase commitments and forecasts against demonstrated demand and inventory risk. Because pharmaceutical commercialization can require coordination among commercial, regulatory, medical, and supply functions, a distributor may support execution but cannot replace the company's accountability for those functions. Put assumptions into a written launch plan with owners, dates, budget, target accounts, and measurable milestones. Review progress against agreed indicators, and revise activities when evidence differs from forecasts, without treating projected outcomes as guaranteed, and flag emerging constraints early.

Set Contract Terms and Review Performance

Before appointing a pharmaceutical distributor, put the commercial arrangement in writing: define territory, permitted channels, exclusivity conditions, and each party's responsibilities. dоcument forecasts as planning assumptions, distinguishing them from purchase commitments, and specify inventory ownership, replenishment rules, and any handling of unsold stock. Set reporting frequency, data fields, service levels, and escalation timelines so operational expectations can be measured. Agreements should also assign complaint intake, investigation, safety escalation, and regulatory notifications, with roles aligned to applicable requirements.

Specify termination, notice, and transition duties for customers, records, and stock. Track fulfillment, forecast accuracy, and complaint resolution; dоcument indicators, regular review meetings, and corrective actions. Israel Figa's business-development context, outlined at https://powerbusiness.co.il/author/israelfiga/, informs disciplined US market entry. Obtain legal and regulatory review before signing.

A U.S. distributor should be assessed against the product's regulatory, operational, and commercial needs. Companies can use a consistent checklist to compare potential partners and identify gaps before signing an agreement. The right decision depends on evidence of fit, not on broad claims of reach alone.

Clear expectations are important after appointment. Defined responsibilities, reporting measures, inventory procedures, and review points give both parties a basis for managing performance. Contract terms should also address practical contingencies, including changes in demand or the relationship.

Market preparation is an ongoing process rather than a single selection decision. Companies should revisit the partner's performance as products, customer needs, and business priorities evolve. A disciplined approach helps teams make better-informed choices while keeping commercial plans grounded in verifiable capabilities.